What topics does this cannabis study cover?

This study covers research on: CBD, Cancer, Inflammation.

Where was this research published?

Published in Biochemical pharmacology on April 9, 2026.

Could CBD disrupt the tumor signals that help oral cancer spread?

Q: What did this Review find?

The review proposes that *CBD* may have anticancer effects in *OSCC* by **modulating extracellular vesicle secretion**, a mechanism that could disrupt tumor communication and progression.

Inhibition of extracellular vesicle secretion by cannabidiol: A promising approach for oral squamous cell carcinoma therapy.

Biochemical pharmacology • April 9, 2026 • Review • Highly Relevant

🤖

AI Summary

Cannabidiol (CBD) is being investigated as a potential treatment strategy for oral squamous cell carcinoma (OSCC), an aggressive oral cancer with limited therapeutic options. This review focuses on extracellular vesicles (EVs)—tiny particles released by cells that help tumors communicate, alter their surroundings, spread, grow new blood vessels, and resist treatment. The authors suggest that CBD’s possible anticancer activity may partly involve reducing or changing EV secretion.

Evidence from non-OSCC research indicates that CBD could influence EV production through pathways involving Wnt/β-catenin, STAT3 signaling, and mitochondrial calcium regulation. However, direct evidence in OSCC models remains limited, and the review presents this mechanism as a promising hypothesis rather than a proven treatment effect. No quantitative clinical or treatment outcomes are reported in the abstract. Major barriers include CBD’s limited bioavailability, the lack of targeted delivery systems, and insufficient OSCC-specific research. Future studies should test long-term effects, CBD-drug combinations, advanced delivery methods, and CBD’s potential dual role in tumor control and pain management.

💡 Key Findings

The review proposes that CBD may have anticancer effects in OSCC by modulating extracellular vesicle secretion, a mechanism that could disrupt tumor communication and progression.

Moderate

50%

Research in non-OSCC systems suggests that CBD may affect EV biogenesis and release through Wnt/β-catenin, STAT3, and mitochondrial calcium pathways.

Moderate

45%

Direct evidence in OSCC models is limited, so the proposed link between CBD, EV regulation, and oral cancer therapy remains hypothetical.

High

80%

Clinical translation is constrained by CBD’s bioavailability, limited delivery specificity, poorly characterized EV regulation in OSCC, and a scarcity of OSCC-specific studies.

Good

75%

📄 Original Abstract

Cannabidiol (CBD), a bioactive phytochemical derived from Cannabis sativa, exhibits anti-inflammatory, antioxidant, and emerging antitumor properties. Oral squamous cell carcinoma (OSCC), the most common oral cancer, remains challenging to treat due to its aggressive nature and limited therapeutic options. Extracellular vesicles (EVs) have been increasingly recognized as key mediators of tumor progression, facilitating intercellular communication, remodeling the tumor microenvironment (TME), and promoting metastasis, angiogenesis, and chemoresistance in OSCC. This review discusses the pharmacological properties of CBD, including its bioavailability limitations, multi-target mechanisms, and potential for combination therapy. Notably, we explore the hypothesis that CBD may exert antitumor effects through modulation of EV secretion-a novel and underexplored mechanism in OSCC. Although direct evidence in OSCC models remains limited, studies in non-OSCC systems suggest that CBD influences EV biogenesis and release via pathways involving Wnt/β-catenin, STAT3 signaling, and mitochondrial calcium homeostasis. Based on these findings, we propose a hypothetical framework linking CBD-mediated EV modulation to OSCC therapy. Despite its therapeutic promise, the clinical translation of CBD faces key hurdles, including poorly characterized mechanisms of EV regulation in OSCC, a lack of targeted delivery systems that compromises specificity and bioavailability, and a general scarcity of OSCC-specific evidence. This review underscores the urgent need for future research to prioritize long-term evaluations, explore synergistic CBD-drug combinations, develop advanced CBD delivery systems, and assess its dual role in tumor suppression and pain management to enable clinical use.

Paper Type

📚 Review

Publication

Journal: Biochemical pharmacology
Published: April 9, 2026
PMID: 41966486
DOI: 10.1016/j.bcp.2026.117948

Authors (11)

Xiaolin Feng Department of Basic Oral Medicine, School and Hospital of Stomatology, Guangdong Engineering Research Center of Oral Restoration and Reconstruction, Guangzhou Medical University, Guangzhou 510812, China.
Chi Zhang Department of Basic Oral Medicine, School and Hospital of Stomatology, Guangdong Engineering Research Center of Oral Restoration and Reconstruction, Guangzhou Medical University, Guangzhou 510812, China.
Zihao Chen Department of Basic Oral Medicine, School and Hospital of Stomatology, Guangdong Engineering Research Center of Oral Restoration and Reconstruction, Guangzhou Medical University, Guangzhou 510812, China.
Zhen Chen Department of Basic Oral Medicine, School and Hospital of Stomatology, Guangdong Engineering Research Center of Oral Restoration and Reconstruction, Guangzhou Medical University, Guangzhou 510812, China.
Ziyang Zhang Department of Basic Oral Medicine, School and Hospital of Stomatology, Guangdong Engineering Research Center of Oral Restoration and Reconstruction, Guangzhou Medical University, Guangzhou 510812, China.
+6 more authors